Idorsia's Invitation to the Annual General Meeting
Idorsia Ltd (SIX: IDIA) is enthusiastic to announce the invitation to its upcoming Annual General Meeting (AGM) for Shareholders. The Board of Directors will oversee this significant event, which will take place at the Congress Center, Messe Basel. Attendees will discuss vital matters, including the approval of the Annual Report for the previous year.
Key Highlights of the Meeting
The AGM is set for Wednesday, May 28, 2025, at 09:00 CEST. This meeting will not only allow shareholders to vote on crucial issues but also provide insights into the company's future plans. The Board is committed to transparency, and important updates will be shared regarding Idorsia's progress over the past year.
Chairman's Statement
Jean-Paul Clozel, the Chairman of the Board, expressed gratitude towards all Board members for their relentless dedication. He remarked on the efforts made to secure the future of Idorsia. Notably, Dr. Sophie Kornowski will not seek re-election for personal reasons, and her contributions over the last two years have been invaluable. All other Board members will stand for re-election, demonstrating the Board's ongoing commitment to stability and continuity.
Shareholder Participation
To participate in the AGM, shareholders must ensure their registration in the company's shareholder register by May 19, 2025, at 17:00 CEST. This step is crucial to have a voice in the decision-making process at the meeting.
Agenda for the Annual General Meeting
The meeting's agenda outlines several key points that shareholders will deliberate upon:
- Annual reporting for 2024, including the vote on the Annual Report, Consolidated Financial Statements, and Statutory Financial Statements
- Consultative votes on the Compensation and Sustainability Reports for 2024
- Decisions on the appropriation of available earnings and the discharge of the Board of Directors
- Amendments to the Articles of Association regarding share capital, including an increase in conditional share capital
- Re-elections of the Board of Directors and its Chair, as well as key committee members
- Voting on Board and Executive Committee compensation for the upcoming term
- Re-election of the Independent Proxy and statutory auditors
Idorsia's Vision and Commitments
Idorsia is committed to pushing the boundaries of scientific discovery and developing transformative medicines for patients worldwide. The company aims to challenge conventional medical paradigms, focusing on questions that have the most significant impact on patient care. With its headquarters located near Basel, a hub for biotech innovations in Europe, Idorsia is well-positioned to lead in the biopharmaceutical field.
Looking Ahead with Innovation
Idorsia continues to emphasize its dedication to research and development. Notably, its flagship product QUVIVIQ™ (daridorexant) represents a revolutionary advancement in insomnia treatment. The team at Idorsia remains steadfast in its mission to enhance patient outcomes and innovate in small-molecule drug discovery.
Contact Information for Investors and Media
For any further inquiries, please reach out to Idorsia’s Investor & Media Relations team. Their office is located at Hegenheimermattweg 91, CH-4123 Allschwil, and they can be contacted at +41 58 844 10 10 or via email at investor.relations@idorsia.com or media.relations@idorsia.com. More information can also be found at www.idorsia.com.
Frequently Asked Questions
What is the purpose of the Idorsia Annual General Meeting?
The AGM serves as an opportunity for shareholders to vote on key company matters, including financial reports and board elections.
When will the AGM take place?
The Annual General Meeting is scheduled for May 28, 2025, at 09:00 CEST.
Who can attend the AGM?
Only registered shareholders in the company’s shareholder register by the given date can attend and vote at the AGM.
How can shareholders prepare for the AGM?
Shareholders should ensure their registration is up to date and review the agenda to understand the matters to be voted on.
What is Idorsia's main focus in the biopharmaceutical market?
Idorsia is focused on discovering and developing innovative therapeutics, particularly in addressing unmet medical needs and advancing existing treatment paradigms.
